Company Overview and News
Stocks were flat in the early morning hours on Thursday, but futures turned higher on all three major U.S. equity indexes. The markets are back to challenging their highs as well, but not necessarily in international and emerging markets. As many investors have seen lower upside from buying on market pullbacks than in prior years, they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
VIA CATR CAT AMD NVDA RHT DO ARGX TRI MS RIG BRKR
Bruker Corporation (BRKR - Free Report) recently announced its decision to acquire Germany-based Hain Lifesciences GmbH, a developer, manufacturer and distributor of molecular diagnostics (MDx) solutions. The acquisition is expected to boost Bruker’s microbiology and diagnostics business.
MASI ISRG BRKR
The following slide deck was published by Bruker Corporation in conjunction with their 2018 Q2 earnings call.
Bruker Corporation (BRKR - Free Report) reported adjusted earnings per share (EPS) of 25 cents in the second quarter of 2018, up 8.7% from the year-ago figure. Adjusted EPS remained in line with the Zacks Consensus Estimate.
ALGN ISRG CHE BGSF FUN BRKR
Good afternoon, everyone, and welcome to the Bruker Q2 2018 Earnings Release Conference Call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please also note, today's event is being recorded.
The opportunities investors miss by relying on screens, when a non-actionable thesis can be just as valuable as an actionable one and the importance of being able to effectively communicate your thesis are topics discussed.
WFCNP AMID HTA SXE BAC NSH MLUSG SYK USG NNBR USCR WFC DOOR DDR DOC USGPF RVI.WI CNMD JPM RVI ITW NS DDR.WI DHR BRKR NPO
Keeping in line with the company’s product expansion strategy, Bruker Corporation (BRKR - Free Report) recently introduced a broad line of mass spectrometry products and workflows at the ASMS (American Society for Mass Spectrometry) conference. The company claims these products to act as breakthroughs in life-science research, in clinical research and large-cohort validations in phenomics and proteomics, in biopharma applications and in applied toxicology and forensics markets.
AMED ISRG ILMN BRKR
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET